Research question: What can the reported potency of YAP-TEAD Inhibitor 1 (Peptide 17) tell us about Hippo pathway biology, and where does interpretation require caution?
What molecular event is being targeted?
The Hippo pathway helps regulate whether cells maintain growth-associated transcriptional programs or enter states associated with growth restraint and apoptosis. YAP, or Yes-associated protein, is a transcriptional coactivator rather than a DNA-binding transcription factor. TEAD proteins provide the DNA-binding component of a transcriptional complex, while YAP contributes activation functions that can influence expression of growth-regulatory genes.
The central molecular event described for this material is disruption of the YAP–TEAD protein-protein interaction. The product documentation identifies YAP-TEAD Inhibitor 1 (Peptide 17) as a cyclic peptide designed to compete with YAP for its interaction with TEAD. In conceptual terms, the causal chain is: inhibitor engagement at the protein interface, reduced formation or stability of the YAP–TEAD complex, lower activity of YAP–TEAD-dependent transcriptional programs, and potentially altered cell-state readouts.
That chain is biologically plausible, but each step represents a different measurement level. A direct binding or interaction assay measures the molecular interface itself. A transcriptional reporter measures a downstream consequence that also depends on DNA elements, cofactors and cellular context. Proliferation or apoptosis measurements are still further downstream and integrate many signaling pathways. A change at one level therefore does not automatically establish an equivalent change at the next.
How should the reported 25 nM IC50 be read?
The documentation reports an IC50 of 25 nM and describes the compound as a potent, competitive inhibitor of the YAP–TEAD interaction. An IC50 is the concentration associated with 50% inhibition under the conditions and assay model used to generate that value. It is not identical to a binding constant, and it cannot by itself establish the concentration required to produce a defined effect in living cells.
For a protein-protein interaction inhibitor, the reported number is most informative as a measure of how strongly the material interfered with the measured molecular interaction in that particular assay format. Its interpretation depends on factors such as the concentrations of the interacting proteins, assay design and the relationship between inhibitor binding and the measured signal. Consequently, the value supports a mechanistic claim about YAP–TEAD interference, but not a universal potency ranking across unrelated assays.
| Reported or conceptual level | What it can indicate | What it does not establish alone |
|---|---|---|
| YAP–TEAD interaction | Direct interference with the named protein interface | Downstream transcriptional or cellular response |
| YAP–TEAD-dependent transcription | Functional effect on a pathway-linked gene-regulatory output | That all YAP-regulated genes respond in the same way |
| Cell proliferation or apoptosis | Integrated change in cell behavior | That YAP–TEAD disruption is the only cause of the phenotype |
Why can biochemical and cellular results differ?
A biochemical assay presents a comparatively defined molecular system. Cellular assays add barriers and sources of variation, including peptide stability, access to the relevant intracellular compartment, endogenous protein abundance, competing protein interactions and the baseline state of Hippo pathway signaling. A compound can therefore show strong biochemical inhibition without producing the same magnitude of pathway modulation in cells.
The reverse interpretive problem also matters. A cellular phenotype such as reduced proliferation may be consistent with reduced YAP–TEAD activity, but it can also reflect broader stress responses or effects on other cellular processes. Strong causal attribution requires concordance between a direct interaction readout, a pathway-proximal transcriptional readout and a phenotype, together with evidence that the phenotype tracks the intended molecular mechanism. The product description alone does not report such a chain of results.
What do the material descriptors contribute?
The documentation gives a molecular weight of 2019.86 Da and the molecular formula C93H144ClN23O21S2. It also reports solubility values in water, ethanol and dimethyl sulfoxide. These are physicochemical descriptors that help define the material being discussed; they are not measurements of YAP–TEAD inhibition, cellular uptake or biological selectivity.
The peptide character is particularly relevant to interpretation because a large cyclic peptide may behave differently from a small-molecule pathway modulator in terms of distribution, stability and access to intracellular targets. Those principles explain why the reported biochemical IC50 should not be translated directly into a cellular exposure threshold. They do not, however, establish the performance of this specific material in any unreported biological model.
What does this mean for YAP-related cancer research?
The documented mechanism gives the material a clear conceptual place in cancer biology research focused on the Hippo pathway: it is intended to interrogate whether disrupting YAP–TEAD assembly changes transcriptional programs associated with tumor initiation or progression. That is a research scope, not a reported demonstration of tumor suppression. The most defensible interpretation is that the material provides a molecular perturbation centered on the YAP–TEAD interface, while the biological significance of that perturbation depends on the model and readout.
Bottom line: The reported 25 nM IC50 supports the description of Peptide 17 as a potent biochemical YAP–TEAD protein-protein interaction inhibitor in the documented assay context. It does not, by itself, establish intracellular activity, selectivity across the wider Hippo network, effects on proliferation or apoptosis, or therapeutic efficacy. Product identity and physicochemical data define the material and its stated mechanism, but broader conclusions require independently reported, model-specific evidence.